Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

NCT01171105
View directory record Official record
Conditions
Healthy
Interventions
AZD5213, Placebo to AZD5213
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT02871570
View directory record Official record
Conditions
Moderate Hepatic Impairment, Normal Hepatic Function
Interventions
Rivipansel
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Jul 21, 2026, 5:41 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study Of PF-05161704 In Healthy Volunteers

NCT01202266
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05161704 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

NCT02415439
View directory record Official record
Conditions
Healthy
Interventions
VBP15, Placebo
Drug
Lead sponsor
ReveraGen BioPharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

NCT05702983
View directory record Official record
Conditions
Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Interventions
STSA-1002 subcutaneous injection
Drug
Lead sponsor
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Industry
Eligibility
21 Years to 57 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

NCT00799006
View directory record Official record
Conditions
Overweight
Interventions
Placebo, PF-04620110
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 19, 2009 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

NCT01655771
View directory record Official record
Conditions
Constipation
Interventions
TD-1211 Dose 1, TD-1211 Dose 2
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects

NCT01369836
View directory record Official record
Conditions
Healthy
Interventions
Tafamidis meglumin, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Jul 21, 2026, 5:41 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants

NCT07222709
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-1042, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Norketotifen in Healthy Subjects

NCT03712163
View directory record Official record
Conditions
Healthy Subjects
Interventions
Norketotifen Oral Capsule (Cohort 1), Norketotifen Oral Capsule (Cohort 2), Norketotifen Oral Capsule (Cohort 3), Norketotifen Oral Capsule (Multiple Dose Cohort), Placebo Oral Capsule
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

NCT02148744
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
Interventions
XmAb7195, Placebo
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Lasmiditan in Healthy Participants

NCT03182920
View directory record Official record
Conditions
Healthy
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Jul 21, 2026, 5:41 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin

NCT01262690
View directory record Official record
Conditions
Cachexia
Interventions
PF-05230901
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects

NCT01657890
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Healthy Volunteers, Safety and Tolerability in Elderly
Interventions
isavuconazole
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of KINE-101 in Healthy Volunteers

NCT07343323
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KINE-101, Placebo
Drug
Lead sponsor
Kine Sciences Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

NCT04005807
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BPN-14967, Placebo
Drug
Lead sponsor
Belite Bio, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

NCT01277692
View directory record Official record
Conditions
Hepatitis C
Interventions
GSK2336805 10mg, GSK2336805 30mg, GSK2236805 100mg, GSK2236805 200mg, GSK2236805 10mg, GSK2236805 dose to be determined up to 100mg, GSK2236805 5mg, GSK2236805 30mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Chula Vista, California • Lenexa, Kansas • Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

NCT02572349
View directory record Official record
Conditions
Healthy
Interventions
IW-1701, Matching Placebo
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects

NCT01702649
View directory record Official record
Conditions
Healthy Volunteers, Bacterial Infections
Interventions
RPX2003 (Biapenem), Placebo
Drug
Lead sponsor
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study of CD101 IV in Healthy Subjects

NCT02516904
View directory record Official record
Conditions
Healthy
Interventions
CD101 IV, Placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and PK of Nikkomycin Z in Healthy Subjects

NCT00834184
View directory record Official record
Conditions
Healthy
Interventions
nikkomycin Z
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 21, 2026, 5:41 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

NCT06673238
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-722, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Cypress, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 21, 2026, 5:41 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients

NCT07051629
View directory record Official record
Conditions
Epilepsy, Healthy Volunteer
Interventions
SIF001, Placebo
Biological · Drug
Lead sponsor
Suninflam Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
10
States / cities
Tucson, Arizona • DeLand, Florida • Tamarac, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus

NCT02250222
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LGD-6972, Placebo (Captisol ®)
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Tempe, Arizona • Miami, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Jul 21, 2026, 5:41 PM EDT